Press release
Assay Designs Launches First Commercially Available EIA Kit for the Measurement of Circulating Hsp70
In February 2008, Assay Designs™ launched the Hsp70 High Sensitivity EIA Kit (Cat. #EKS-715). This kit is for the accurate and specific quantification of as little as 90 pg/mL of inducible Hsp70 in serum and plasma samples from human, mouse, and rat origin. This assay does not significantly cross react with other Hsp70 family members such as Hsc70 (Hsp73), Grp78, DnaK (E. coli), or Hsp71 (M. tuberculosis) allowing for accurate and specific quantitation of Hsp70 in samples.Assay Designs Hsp70 High Sensitivity EIA Kit is the only product commercially available that is validated for the measurement of circulating Hsp70. This product has been specifically optimized for use with serum and plasma, but has not been extensively validated for use with other sample matrices. The Hsp70 High Sensitivity EIA Kit features liquid color-coded reagents and a pre-coated 96 well plate that save lab time and reduce error. There is no need for cumbersome Western blot analysis of serum and plasma samples. A simple dilution of samples in the supplied kit assay buffer allows for the higher throughput analysis of up to 39 samples in duplicate per 96 wells in just 4.5 hours. As scientists, Assay Designs understands the critical nature of research and takes every step to ensure that their products meet the highest quality standards for sensitivity, specificity, and reproducibility to reduce repeat experiments.
Hsp70 is a molecular chaperone whose expression is induced upon exposure of the cell or organism to conditions of stress. It prevents protein aggregation and promotes the refolding of proteins that become damaged in response to environmental insults, pathogens, and disease. Its activity is essential for cellular survival and recovery under stress conditions, as well as for the maintenance of normal cellular function under non-stress conditions. Hsp70 has been implicated to play a role in a variety of disease and physiological processes such as hyperthermia, hypertension, toxic exposure to chemical agents, hypoxia, ischemia, inflammation, autoimmunity, apoptosis, cancer, organ transplantation, and bacterial and viral infections. Hsp70 is a key regulator of many normal physiological processes including aging, spermatogenesis, menstruation, and physical activity such as exercise. The Assay Designs High Sensitivity Hsp70 EIA kit is designed to evaluate and monitor Hsp70 in these processes, and provides a key research tool for the investigation of Hsp70’s role in physiology and disease.
Assay Designs, Inc.
5777 Hines Drive
Ann Arbor, MI 48108
800.833.8651
Emily Riesterer
info@assaydesigns.com
www.assaydesigns.com
For over 15 years, Assay Designs has provided high quality antibodies, proteins, and kits for the precise quantification of key small and large molecule biomarkers in a variety of sample matrices and species. Since our merger with Stressgen® Bioreagents in 2005, the Assay Designs portfolio of products has included the full line of Stressgen brand kits and reagents, enabling researchers to investigate biological pathways involved in the cellular response to stress.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Assay Designs Launches First Commercially Available EIA Kit for the Measurement of Circulating Hsp70 here
News-ID: 52019 • Views: …
More Releases for Hsp70
Diabetic Neuropathic Pain - Pipeline Insight, 2025: Innovation in Non-Opioid The …
Diabetic neuropathic pain (DNP), a common and debilitating complication of diabetes, results from long-standing nerve damage due to chronic hyperglycemia. Characterized by burning sensations, tingling, numbness, and sharp pain, DNP severely affects patients' quality of life and functional ability. Despite several treatment options-mainly focused on symptomatic relief-there remains a considerable unmet need for safer, more effective, and disease-modifying therapies that can offer sustained benefits without central nervous system side effects…
Gastric Cancer Pipeline Insights, Treatment Drugs, Clinical Trials and Companies …
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive Gastric Cancer Pipeline…
Vitiligo Pipeline Insights (2024) | Clinical Trials, Latest Approvals, Treatment …
The assessment part of the Vitiligo Pipeline report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
DelveInsight's "Vitiligo - Pipeline…
Bag3-related Gene Therapies Market is Expected to Show a Healthy Growth Rate Dur …
DelveInsight's "Bag3-related Gene Therapies Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Bag3-related Gene Therapies, historical and forecasted epidemiology as well as the Bag3-related Gene Therapies market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Download Sample Report to know more @ https://www.delveinsight.com/sample-request/bag3-related-gene-therapies-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Bag3-related Gene Therapies Overview
BAG family molecular chaperone regulator 3 is a protein that in humans is…
Cervical Dysplasia Pipeline Assessment Report (2023) Covering Clinical Trials, E …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are working on developing new therapies in the Cervical Dysplasia therapeutics landscape based on different Routes of Administration (ROA), Mechanisms of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Cervical Dysplasia Pipeline Insight, 2023" report by…
Exosomes Pipeline Market Drug Profiles, Key Companies Insights and Key Products …
“Exosomes Market- Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes Pipeline Market landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Exosomes Understanding
Exosomes: Overview
Exosomes are small membrane vesicles of endocytic…